Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EP400 pseudogene 1 (EP400P1), also known as EP400NL, is classified as a pseudogene in humans and is not a typical protein-coding gene or established therapeutic target[3][4]. While the gene has been referenced in some literature as involved in PD-L1 gene activation by acting as a transcriptional coactivator (suggesting a possible regulatory function), there is insufficient evidence that the encoded protein is functional or relevant as a drug target [4]. Most available resources (GeneCards, NCBI Gene, UniProt) classify EP400P1 as a pseudogene, and not as a receptor, enzyme, transporter, or transcription factor in the canonical sense[3][5]. No known drugs target EP400P1, and there are no established disease links, mechanisms of action, biomarkers, or safety concerns associated with this locus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EP400 pseudogene 1 (EP400P1).